Merging the properties of a sirolimus coated balloon with those of a bioresorbable polymer sirolimus eluting stent to address the "diabetes issue". Results from the En-Abl multicenter registry

Minerva Cardioangiol. 2018 Oct;66(5):536-542. doi: 10.23736/S0026-4725.18.04702-3. Epub 2018 Apr 20.


Background: Patients with diabetes mellitus (DM) have poorer outcomes after percutaneous coronary intervention than patients without diabetes. The Abluminus DES+™ drug-eluting stent (DES) features a novel technology of fusion coating of PLLA bioresorbable polymer on both the abluminal surface of the stent and exposed parts of the balloon. The aim of this study was to evaluate the efficacy/safety profile of the Abluminus DES+ in an all-comers population with minimal exclusion criteria and with a specific focus on diabetic patients.

Methods: Multicenter, prospective, all-comers registry performed in 31 centers in India. Patients were analyzed according to the diagnosis of DM and insulin dependency (ID or Non ID): non-DM (1256 patients), NIDDM (498 patients), IDDM (99 patients). The primary endpoint was a composite of device-oriented major adverse cardiac events (MACE): cardiac death, target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)/ target vessel revascularization (TVR) at 1 year. Stent thrombosis (ST) at any time point was also recorded.

Results: The MACE rate at 1 year in the overall population was 2.3% and it was mainly driven by a 1.57% rate of TLR/TVR. Although patients with IDDM showed slightly higher figures for MACE (non-DM 2.3%, NIDDM 2.8%, IDDM 4%, P=0.09), as well as for single end-points, none of them reached statistical significance. The rate of ST was 0.56%, 0.4%, 1% for non-DM, NIDDM and IDDM group, respectively (P=0.6).

Conclusions: The performance of the Abluminus DES+ is consistent among patients with or without diabetes, regardless the insulin dependency.

Publication types

  • Multicenter Study

MeSH terms

  • Absorbable Implants
  • Adult
  • Aged
  • Diabetes Mellitus, Type 1 / physiopathology*
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Drug-Eluting Stents* / adverse effects
  • Female
  • Humans
  • India
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Myocardial Ischemia / epidemiology
  • Percutaneous Coronary Intervention / methods
  • Polymers / chemistry
  • Prospective Studies
  • Registries
  • Sirolimus / administration & dosage*
  • Treatment Outcome


  • Polymers
  • Sirolimus